Start the conversation
On Friday, May 31, the U.S. Food & Drug Administration (FDA) held its first-ever hearings on cannabidiol, or CBD.
The event didn't exactly slip under the radar…
Headlines ranged from Jezebel's laughably sensationalistic "Is CBD Over?" to The New York Times' more serious "Cannabis Companies Push FDA to Ease Rules on CBD Products."
This hearing, an all-day affair that lasted from 8 a.m. on Friday till 6 p.m., deserved every second of the coverage it received.
But there's one thing we didn't see covered…
And it's likely exactly the thing needed to push the FDA in the right direction when it comes to CBD regulation…
Regulators Are Facing the Powerful Voice of the People
Friday's hearing featured over 100 speakers.
There were some marijuana "flat-earthers" looking to crack down on CBD and cannabis, and there were plenty of representatives of CBD companies understandably applying pressure on the FDA to loosen those regulations.
But more to the point, there were a great number of regular people, just like you and me, sharing their experiences with CBD products.
About the Author
Greg Miller started working on Wall Street in September, 1987, just a month before the “Black Monday” stock market crash.
During his career there, he became an expert in just about every kind of publicly traded security - from blue-chip and small-cap stocks to municipals, junk bonds, and derivatives. As a portfolio manager, Greg was responsible for over $500 million of assets in mutual funds and insurance company accounts.
After leaving the Street, he designed a successful options trading strategy and made lucrative tech investments for a financial publication. He has also helped develop new products and worked with other editors to hone their strategies. He’s always been dedicated to deep, fundamental research - and he always will be - because he believes buying the very best companies at the right price is the best way to amass wealth in the stock market.